Bookmark

Mechanisms of Disulfiram-induced Cocaine Abstinence: Antabuse and Cocaine Relapse

Gaval-Cruz, Meriem; Weinshenker, David
Molecular Interventions , Volume 9 (4): 175 Am. Soc for Pharma & Experimental TherapeuticsAug 1, 2009

Preview Only

Mechanisms of Disulfiram-induced Cocaine Abstinence: Antabuse and Cocaine Relapse

Abstract

Abstract Chemokines are chemoattractant proteins, secreted by a great many cell types, that function particularly to direct the migration of cells of the immune system. Chemokine receptors are G protein–coupled and have been implicated in a number of important disease states, including cancer, inflammatory disorders, and AIDS/HIV. Neuroinflammatory aspects of chronic pain are also chemokine-dependent, and given the many clinical difficulties that often arise in the treatment of chronic pain, novel therapeutics are urgently needed. Chemokine receptors would thus appear to be in ideal target for drug development, and indeed, animal models of neuropathic pain have allowed pharmacologists to identify a number of cell types and signaling pathways that are essential to the initiation and maintenance of chronic pain. In this regard, the chemokine receptor CCR2, activated by a chemokine known as monocyte chemoattractant protein 1, has been attributed to a number of specific regulatory and neural activation processes that contribute to chronic pain. But in order to target chemokine receptors such as CCR2 and thereby develop effective treatment, investigators must identify, from among many cell types and peripheral and central neural pathways, the relevant sites of CCR2 function.
Loading next page...

Preview Only. This article cannot be rented because we do not currently have permission from the publisher.

 
/lp/am-soc-for-pharma-experimental-therapeutics/mechanisms-of-disulfiram-induced-cocaine-abstinence-antabuse-and-i2P5YspfDU
Title
Mechanisms of Disulfiram-induced Cocaine Abstinence: Antabuse and Cocaine Relapse
Author(s)
Gaval-Cruz, Meriem; Weinshenker, David
Journal
Molecular Interventions , Volume 9 (4): 175 Am. Soc for Pharma & Experimental Therapeutics – Aug 1, 2009
Publisher
American Society for Pharmacology and Experimental Therapeutics
Copyright
Copyright © Molecular Interventions
ISSN
1534-0384
eISSN
1543-2548
D.O.I.
10.1124/mi.9.4.6
Publisher site
Get PDF